CMRA Stock Price, Comera Life Sciences Holdings, . Quote, Chart

Market Summary

USD0.040.00

Delayed

0.00%

CMRA Stock Price

View Fullscreen

CMRA RSI Chart

CMRA Valuation

Market Cap

1.2M

Price/Earnings (Trailing)

-0.2

Price/Sales (Trailing)

1.84

Price/Free Cashflow

-0.27

CMRA Price/Sales (Trailing)

CMRA Profitability

Operating Margin

73.52%

Return on Equity

-24.53%

Return on Assets

-293.27%

Free Cashflow Yield

-366.27%

CMRA Fundamentals

CMRA Revenue

Revenue (TTM)

1.0M

Rev. Growth (Yr)

-41.98%

Rev. Growth (Qtr)

-56.73%

CMRA Earnings

Earnings (TTM)

-9.0M

Earnings Growth (Yr)

30%

Earnings Growth (Qtr)

-52.57%

Breaking Down CMRA Revenue

Last 30 days

33.3%

Last 90 days

-42.9%

How does CMRA drawdown profile look like?

CMRA Financial Health

Current Ratio

0.9

CMRA Investor Care

Shares Dilution (1Y)

54.86%

Diluted EPS (TTM)

1.53

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	930.7K	1.1M	1.0M	0
2022	327.4K	403.2K	550.3K	633.1K
2021	0	401.9K	360.9K	319.8K
2020	0	0	0	442.9K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Comera Life Sciences Holdings, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 27, 2023	campbell michael gerard	bought	708	0.0708	10,000	evp & cfo
Nov 15, 2023	wexler william a.	acquired	-	-	3,113	-
Sep 11, 2023	soane david	bought	29,997	0.5112	58,680	-
Sep 11, 2023	cherington charles	bought	1,049,900	0.5112	2,053,790	-
Aug 14, 2023	mahoney robert patrick	bought	12,504	0.6252	20,000	chief scientific officer
Aug 11, 2023	wexler william a.	acquired	-	-	6,636	-
Jul 31, 2023	soane david	bought	69,993	0.5112	136,919	-
Jul 31, 2023	cherington charles	bought	450,044	0.5113	880,195	-
Jan 04, 2023	sherblom james	bought	99,729	1.23	81,081	-
Jan 04, 2023	soane david	bought	166,215	1.23	135,134	-

Which funds bought or sold CMRA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-12,855	-	-%
Feb 26, 2024	Privium Fund Management B.V.	sold off	-100	-922	-	-%
Feb 15, 2024	GTS SECURITIES LLC	sold off	-100	-207	-	-%
Feb 14, 2024	STATE STREET CORP	sold off	-100	-9,442	-	-%
Feb 14, 2024	Walleye Capital LLC	sold off	-100	-1,344	-	-%
Feb 14, 2024	CLEAR STREET LLC	added	0.33	-1,000	-	-%
Feb 14, 2024	LMR Partners LLP	new	-	300	300	-%
Feb 14, 2024	Verition Fund Management LLC	sold off	-100	-315	-	-%
Feb 14, 2024	RIVERNORTH CAPITAL MANAGEMENT, LLC	unchanged	-	-1,402	225	-%
Feb 14, 2024	Walleye Trading LLC	sold off	-100	-756	-	-%

Are Funds Buying or Selling CMRA?

Are funds buying CMRA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CMRA

No. of Funds

Unveiling Comera Life Sciences Holdings, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 08, 2024	cherington charles	66.31%	45,989,871	SC 13D

Recent SEC filings of Comera Life Sciences Holdings, Inc.

View All Filings

Date Filed	Form Type	Document
Feb 27, 2024	EFFECT	EFFECT
Feb 27, 2024	EFFECT	EFFECT
Feb 27, 2024	EFFECT	EFFECT
Feb 27, 2024	EFFECT	EFFECT
Feb 26, 2024	S-8 POS	Employee Benefits Plan
Feb 26, 2024	8-K	Current Report
Feb 26, 2024	POS AM	POS AM
Feb 26, 2024	POS AM	POS AM
Feb 26, 2024	POS AM	POS AM
Feb 26, 2024	POS AM	POS AM

Peers (Alternatives to Comera Life Sciences Holdings, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.2	12.55	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.93	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Comera Life Sciences Holdings, Inc. News

Latest updates

Comera Life Sciences Holdings, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)											(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Revenue	-56.7%	136	315	393	156	235	147	95.00	73.00	88.00	71.00	-
Cost Of Revenue	-25.1%	42.00	56.00	117	50.00	61.00	55.00	45.00	39.00	48.00	58.00	-
Operating Expenses	29.4%	2,251	1,739	2,777	3,115	2,709	4,065	2,503	2,059	953	1,917	-
S&GA Expenses	25.4%	1,885	1,504	2,433	2,626	2,315	3,697	2,016	1,568	689	1,238	-
R&D Expenses	55.3%	366	236	344	489	395	369	487	490	264	680	-
Interest Expenses	50.0%	6.00	4.00	8.00	8.00	13.00	-	77*	-	-	-	-
Net Income	-52.6%	-2,153	-1,411	-2,481	-2,962	-3,076	-9,085	-2,879	-2,024	-913	-1,980	-
Net Income Margin	0.4%	-9.01*	-9.04*	-18.92*	-28.44*	-31.01*	-36.96*	-23.82*	-17.05*	-6.06*	-5.57*	-4.80*
Free Cashflow	-91.6%	-1,914	-999	-1,994	-1,847	-2,414	-2,795	-3,000	-1,734	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet									(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q4
Assets	31.3%	3,072	2,340	2,999	3,727	4,937	6,131	6,774	7,418	546
Current Assets	44.2%	2,630	1,824	2,407	3,063	4,289	5,411	-	6,781	310
Cash Equivalents	271.2%	1,768	476	1,539	447	2,669	4,939	3,863	6,560	180
Net PPE	-11.0%	187	210	235	257	193	216	-	234	178
Liabilities	-25.8%	2,970	4,000	3,659	5,456	3,933	3,578	2,412	1,247	394
Current Liabilities	-25.8%	2,932	3,954	3,355	5,059	3,430	2,524	-	1,045	233
LT Debt, Current	-33.3%	390	585	-	456	911	-	-	-	-
Shareholder's Equity	13.2%	36,727	32,445	32,118	28,655	28,512	27,071	2,685	2,214	10,681
Retained Earnings	-5.5%	-40,950	-38,800	-37,385	-34,903	-31,941	-28,864	-	-16,899	-11,448
Additional Paid-In Capital	13.2%	36,727	32,445	32,118	28,655	28,512	27,071	-	2,214	919
Shares Outstanding	60.5%	30,738	19,155	19,153	16,709	8,295	4,430	718	308	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)											(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Cashflow From Operations	-92.7%	-1,914	-993	-1,905	-1,847	-2,389	-2,665	-2,869	-1,603	-933	-	-
Share Based Compensation	-4.1%	268	279	301	149	128	57.00	43.00	42.00	34.00	1,024	-
Cashflow From Investing	100.0%	-	-5.65	-88.36	-	-25.15	-	-	-	-	-	-
Cashflow From Financing	5172.3%	3,206	-63.20	1,581	1,131	145	3,744	223	-	2,290	-	-

CMRA Income Statement

2023-09-30

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Revenue	$ 136,310	$ 234,922	$ 844,280	$ 476,982
Cost of revenue	41,961	60,963	214,520	160,030
Operating expenses:
Research and development	366,015	394,800	945,415	1,250,570
General and administrative	1,885,405	2,314,554	5,822,107	8,027,316
Total operating expenses	2,251,420	2,709,354	6,767,522	9,277,886
Loss from operations	(2,157,071)	(2,535,395)	(6,137,762)	(8,960,934)
Other income (expense), net:
Change in fair value of derivative warrant liabilities	9,325	500,327	108,678	1,954,767
Reverse recapitalization issuance costs in excess of gross proceeds				(6,566,821)
Common stock purchase agreement issuance costs		(1,029,077)		(1,029,077)
Interest expense	(5,965)	(12,696)	(17,559)	(12,773)
Other expense, net				(426,666)
Total other income (expense), net	3,360	(541,446)	91,119	(6,080,570)
Net loss and comprehensive loss	(2,153,711)	(3,076,841)	(6,046,643)	(15,041,504)
Less: accretion of convertible preferred stock to redemption value	(85,468)	(86,816)	(258,156)	(287,984)
Net loss attributable to common stockholders	$ (2,239,179)	$ (3,163,657)	$ (6,304,799)	$ (15,329,488)
Net loss per share attributable to common stockholders - basic	$ (0.1)	$ (0.2)	$ (0.31)	$ (1.85)
Net loss per share attributable to common stockholders - diluted	$ (0.1)	$ (0.2)	$ (0.31)	$ (1.85)
Weighted-average number of common shares used in computing net loss per share attributable to common stockholders - basic	23,113,051	16,024,011	20,448,666	8,294,938
Weighted-average number of common shares used in computing net loss per share attributable to common stockholders - diluted	23,113,051	16,024,011	20,448,666	8,294,938

CMRA Balance Sheet

2023-09-30

Consolidated Balance sheets (Unaudited) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 1,767,870	$ 446,607
Restricted cash - current		1,505,625
Accounts receivable		34,320
Deferred issuance costs		90,047
Prepaid expenses and other current assets	862,626	986,499
Total current assets	2,630,496	3,063,098
Restricted cash - non-current	50,000	50,000
Property and equipment, net	186,738	257,186
Right of use asset	161,515	313,629
Security deposit	43,200	43,200
Total assets	3,071,949	3,727,113
Current liabilities:
Accounts payable	1,144,822	1,458,267
Accrued expenses and other current liabilities	1,226,129	1,295,764
Insurance premium financing	389,872	455,562
Deposit liability		1,505,625
Deferred revenue		144,280
Lease liability - current	171,596	199,184
Total current liabilities	2,932,419	5,058,682
Derivative warrant liabilities	37,266	277,507
Lease liability - noncurrent		120,302
Total liabilities	2,969,685	5,456,491
Commitments and contingencies (Note 15)
Stockholders' deficit:
Common stock, $0.0001 par value; 150,000,000 shares authorized; 30,737,796 and 16,709,221 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	2,759	1,671
Additional paid-in capital	36,727,205	28,655,164
Accumulated deficit	(40,950,566)	(34,903,923)
Total stockholders' deficit	(4,220,602)	(6,247,088)
Total liabilities, convertible preferred stock and stockholders' deficit	3,071,949	3,727,113
Series A Convertible Preferred Stock
Current liabilities:
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; 3,895.53 and 4,305 shares designated Series A convertible preferred stock at September 30, 2023 and December 31, 2022; 3,895.53 and 4,305 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	$ 4,322,866	$ 4,517,710

About Comera Life Sciences Holdings, Inc.

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

CEO	Mr. Jeffrey S. Hackman
WEBSITE	https://comeralifesciences.com
INDUSTRY	Biotechnology
EMPLOYEES	12

Comera Life Sciences Holdings, Inc. Frequently Asked Questions

What is the ticker symbol for Comera Life Sciences Holdings, Inc.? What does CMRA stand for in stocks?

CMRA is the stock ticker symbol of Comera Life Sciences Holdings, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Comera Life Sciences Holdings, Inc. (CMRA)?

As of Fri Apr 26 2024, market cap of Comera Life Sciences Holdings, Inc. is 1.23 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CMRA stock?

You can check CMRA's fair value in chart for subscribers.

What is the fair value of CMRA stock?

You can check CMRA's fair value in chart for subscribers. The fair value of Comera Life Sciences Holdings, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Comera Life Sciences Holdings, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CMRA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Comera Life Sciences Holdings, Inc. a good stock to buy?

The fair value guage provides a quick view whether CMRA is over valued or under valued. Whether Comera Life Sciences Holdings, Inc. is cheap or expensive depends on the assumptions which impact Comera Life Sciences Holdings, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CMRA.

What is Comera Life Sciences Holdings, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, CMRA's PE ratio (Price to Earnings) is -0.2 and Price to Sales (PS) ratio is 1.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CMRA PE ratio will change depending on the future growth rate expectations of investors.